Business
Amarantus to Present at ICV Sonoma Event
Amarantus to Present at ICV Sonoma Event.
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\n\n\n\nAmarantus to Present at ICV Sonoma Event\n\n\n\n\n\nAmarantus to Present at ICV Sonoma Event\nPR Newswire\nSAN FRANCISCO, January 15, 2016\n\n\n\nSAN FRANCISCO, January 15, 2016 /PRNewswire/ --\n\nAmarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapies in Regenerative Medicine and Orphan disease, today announced the Company will be presenting at the ICV Sonoma event. The conference is being held January 14-16, 2016 at Sonoma Golf Club in Sonoma, California. Gerald E. Commissiong, President and CEO of Amarantus, will present on Friday, January 15th, 2016  2:30pm Pacific Time.\n\nMr. Commissiong will discuss details regarding a pending Amarantus Diagnostics, Inc. spin-out transaction into a publicly-traded, immuno-oncology-focused diagnostics company.\n\nFurther information about ICV Sonoma can be found at: http://www.icvevents.com/event/icv-sonoma/\n\nAbout Amarantus Diagnostics \n\nAmarantus Diagnostics, Inc. has the rights to MSPrecise®, a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test®) for Alzheimer's disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for the diagnosis of Parkinson's disease (NuroPro).\n\nAbout Amarantus Bioscience Holdings, Inc. \n\nAmarantus Bioscience Holdings, Inc (OTCQX: AMBS) is focused on developing treatments in the areas of Regenerative Medicine, and Orphan diseases. The Company acquired an exclusive worldwide license to intellectual property rights associated with Engineered Skin Substitute (ESS) from Lonza. ESS is an autologous full thickness skin replacement product in development for the treatment of adult severe burns, currently preparing to enter Phase 2 clinical studies. The Company is currently evaluating human clinical data from previously conducted studies in pediatric severe burns and Congenital Giant Hairy Nevus to support clinical development expansion into those areas.  ESS has achieved Orphan Drug Designation (ODD) in the area of severe burns, and is seeking ODD status for additional serious dermatologic indications. AMBS also has d...